title: Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma.
abstract: Next-generation sequencing (NGS)-based circulating tumour DNA (ctDNA) detection is a promising monitoring tool for lymphoid malignancies. We evaluated whether the presence of ctDNA was associated with outcome after allogeneic haematopoietic stem cell transplantation (HSCT) in lymphoma patients. We studied 88 patients drawn from a phase 3 clinical trial of reduced-intensity conditioning HSCT in lymphoma. Conventional restaging and collection of peripheral blood samples occurred at pre-specified time points before and after HSCT and were assayed for ctDNA by sequencing of the immunoglobulin or T-cell receptor genes. Tumour clonotypes were identified in 87% of patients with adequate tumour samples. Sixteen of 19 (84%) patients with disease progression after HSCT had detectable ctDNA prior to progression at a median of 3·7 months prior to relapse/progression. Patients with detectable ctDNA 3 months after HSCT had inferior progression-free survival (PFS) (2-year PFS 58% vs. 84% in ctDNA-negative patients, P = 0·033). In multivariate models, detectable ctDNA was associated with increased risk of progression/death (Hazard ratio 3·9, P = 0·003) and increased risk of relapse/progression (Hazard ratio 10·8, P = 0·0006). Detectable ctDNA is associated with an increased risk of relapse/progression, but further validation studies are necessary to confirm these findings and determine the clinical utility of NGS-based minimal residual disease monitoring in lymphoma patients after HSCT.
authors.affiliation: Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA.
authors.forename: Alex F
authors.initials: AF
authors.lastname: Herrera
authors.affiliation: Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Haesook T
authors.initials: HT
authors.lastname: Kim
authors.affiliation: Adaptive Biotechnologies Corp., South San Francisco, CA, USA.
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Kong
authors.affiliation: Adaptive Biotechnologies Corp., South San Francisco, CA, USA.
authors.forename: Malek
authors.initials: M
authors.lastname: Faham
authors.affiliation: Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
authors.forename: Heather
authors.initials: H
authors.lastname: Sun
authors.affiliation: Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
authors.forename: Aliyah R
authors.initials: AR
authors.lastname: Sohani
authors.affiliation: Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Edwin P
authors.initials: EP
authors.lastname: Alyea
authors.affiliation: Adaptive Biotechnologies Corp., South San Francisco, CA, USA.
authors.forename: Victoria E
authors.initials: VE
authors.lastname: Carlton
authors.affiliation: Division of Bone Marrow Transplantation, Massachusetts General Hospital, Boston, MA, USA.
authors.forename: Yi-Bin
authors.initials: YB
authors.lastname: Chen
authors.affiliation: Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Corey S
authors.initials: CS
authors.lastname: Cutler
authors.affiliation: Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Vincent T
authors.initials: VT
authors.lastname: Ho
authors.affiliation: Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: John
authors.initials: J
authors.lastname: Koreth
authors.affiliation: Adaptive Biotechnologies Corp., South San Francisco, CA, USA.
authors.forename: Chitra
authors.initials: C
authors.lastname: Kotwaliwale
authors.affiliation: Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Sarah
authors.initials: S
authors.lastname: Nikiforow
authors.affiliation: Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Jerome
authors.initials: J
authors.lastname: Ritz
authors.affiliation: Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
authors.forename: Scott J
authors.initials: SJ
authors.lastname: Rodig
authors.affiliation: Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Soiffer
authors.affiliation: Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Joseph H
authors.initials: JH
authors.lastname: Antin
authors.affiliation: Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Philippe
authors.initials: P
authors.lastname: Armand
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004273:DNA, Neoplasm / Q000097:blood*; D003643:Death; D018450:Disease Progression; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods / Q000592:standards*; D006801:Humans; D007136:Immunoglobulins / Q000235:genetics; D008223:Lymphoma / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000175:diagnosis*; D011948:Receptors, Antigen, T-Cell / Q000235:genetics; D012008:Recurrence; D012189:Retrospective Studies; D017422:Sequence Analysis, DNA; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D004273:DNA, Neoplasm; D007136:Immunoglobulins; D011948:Receptors, Antigen, T-Cell
keywords: chronic lymphocytic leukaemia; lymphomas; minimal residual disease; non-Hodgkin lymphoma; stem cell transplantation